Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    681 result(s) found for: IgA. Displaying page 3 of 35.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-001650-25 Sponsor Protocol Number: CASM981C2440 Start Date*: 2005-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of El...
    Medical condition: Mild to moderate facial atopic dermatitis (AD), in children
    Disease: Version SOC Term Classification Code Term Level
    M15 10003639
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001997-52 Sponsor Protocol Number: 20170755 Start Date*: 2018-12-28
    Sponsor Name:Amgen Inc
    Full Title: A Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tezepelumab Alone or Combined with Topical Corticosteroids in Moderate-to-Severe Atopic Dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002609-22 Sponsor Protocol Number: CAIN457A2309 Start Date*: 2012-10-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab in autoinjectors to demonstrate efficacy after twelve weeks of treatment, and to assess the safety, tol...
    Medical condition: Moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000336-28 Sponsor Protocol Number: CASM981N2301 Start Date*: 2006-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week open-label, single-arm, multi-center study to evaluate the long term safety of pimecrolimus 1% cream intermittent treatment of seborrhoeic dermatitis in patients 12 years of age and older
    Medical condition: Seborrhoeic dermatitis (SD)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000598-19 Sponsor Protocol Number: 115461 Start Date*: 2016-10-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks.
    Medical condition: Rotarix is indicated to prevent infants against gastroenteritis (GE) due to rotavirus (RV).
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10039232 Rotavirus gastroenteritis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) Outside EU/EEA ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002919-15 Sponsor Protocol Number: CLS001-CO-PR-004 Start Date*: 2015-11-16
    Sponsor Name:Cutanea Life Sciences, Inc.
    Full Title: A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subject...
    Medical condition: Papulopustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Ongoing) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000871-41 Sponsor Protocol Number: STOPIgAN Start Date*: 2008-01-24
    Sponsor Name:RWTH Aachen
    Full Title: Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy
    Medical condition: IgA nephropathy (IgAN) as the most common type of glomerulonephritis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002104-18 Sponsor Protocol Number: GID25 Start Date*: 2007-08-27
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an I...
    Medical condition: Vaccination of adult subjects aged 18 to 40 years and elderly subjects aged 60 to 85 years with an inactivated, split-virion influenza vaccine administered via the intradermal route using Vaxigrip®...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003588-24 Sponsor Protocol Number: CAIN457S12201 Start Date*: 2020-04-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A proof of concept study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven forms of lichen planus not adequately controlled ...
    Medical condition: Lichen planus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10024429 Lichen planus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006340-27 Sponsor Protocol Number: LP0133-1426 Start Date*: 2022-04-21
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to evaluate efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adolescents 12-17 ye...
    Medical condition: Chronic Hand Eczema
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004858 10084778 Chronic hand eczema LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) BE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002401-56 Sponsor Protocol Number: I9N-MC-FCAB Start Date*: 2019-04-29
    Sponsor Name:Eli Lilly & Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002960-30 Sponsor Protocol Number: LP0133-1401 Start Date*: 2021-06-15
    Sponsor Name:LEO Pharma A/S
    Full Title: A phase 3 clinical trial to confirm efficacy and evaluate safety of twice-daily delgocitinib cream 20 mg/g compared with cream vehicle for a 16-week treatment period in adult subjects with moderate...
    Medical condition: Chronic Hand Eczema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002716-27 Sponsor Protocol Number: ALN-CC5-005 Start Date*: 2019-06-11
    Sponsor Name:Alnylam Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy
    Medical condition: Immunoglobulin A nephropathy (IgAN)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000720-18 Sponsor Protocol Number: CNTO1959PSO3002 Start Date*: 2015-02-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004635-29 Sponsor Protocol Number: ASF-1096-301 Start Date*: 2007-11-07
    Sponsor Name:Astion Pharma A/S
    Full Title: Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice dail...
    Medical condition: Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002176-75 Sponsor Protocol Number: CZPL389A2203 Start Date*: 2019-11-05
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double blind, placebo controlled multicenter dose ranging study to assess the safety and efficacy of multiple oral ZPL389 doses in patients with moderate to severe Atopic Dermatitis (...
    Medical condition: Moderate to severe atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) FI (Prematurely Ended) IS (Completed) AT (Prematurely Ended) EE (Prematurely Ended) BE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) FR (Prematurely Ended) ES (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002531-29 Sponsor Protocol Number: VIS649-201 Start Date*: 2020-03-24
    Sponsor Name:Visterra, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy
    Medical condition: Immunoglobulin A (IgA) Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003239-61 Sponsor Protocol Number: 107876 Start Date*: 2006-09-29
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomised study to evaluate the clinical consistency in terms of immunogenicity and reactogenicity of three production lots of the liquid formulation of GlaxoSmithKline (GSK) Biologic...
    Medical condition: Two-dose immunisation at 3 and 4 months of age in healthy infants previously uninfected with HRV.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-002610-37 Sponsor Protocol Number: SIREPNA/05 Start Date*: 2005-12-05
    Sponsor Name:NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE)
    Full Title: PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS. Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas d...
    Medical condition: To test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006208-21 Sponsor Protocol Number: ELKE-2006 Start Date*: 2006-10-23
    Sponsor Name:Department of Dermatology, University of Kiel
    Full Title: Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and diff...
    Medical condition: Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:04:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA